Hjem
Olav Dahls bilde

Olav Dahl

Professor
  • E-postOlav.Dahl@uib.no
  • Telefon+47 55 97 20 18
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2013). Investigation of six testicular germ cell tumor susceptibility genes suggests a parent-of-origin effect in SPRY4. Human Molecular Genetics. 3373-3380.
  • Vis forfatter(e) (2013). Impaired health-related quality of life after chemoradiotherapy for anal cancer: Late effects in a national cohort of 128 survivors. Acta Oncologica. 736-744.
  • Vis forfatter(e) (2013). Genetic variation in AKT1, PTEN and the 8q24 locus, and the risk of testicular germ cell tumor. Human Reproduction. 1995-2002.
  • Vis forfatter(e) (2013). Faecal incontinence after chemoradiotherapy in anal cancer survivors: Long-term results of a national cohort. Radiotherapy and Oncology. 55-60.
  • Vis forfatter(e) (2012). High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA). Acta Oncologica. 168-176.
  • Vis forfatter(e) (2012). Gene variations in sex hormone pathways and the risk of testicular germ cell tumour: a case-parent triad study in a Norwegian-Swedish population. Human Reproduction. 1525-1535.
  • Vis forfatter(e) (2012). Fibroblast growth factor 2—A predictor of outcome for patients irradiated for stage II-III non–small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 442-447.
  • Vis forfatter(e) (2012). Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients. British Journal of Cancer. 756-762.
  • Vis forfatter(e) (2011). Prognostic impact of erythropoietin expression and erythropoietin receptor expression on locoregional control and survival of patients irradiated for stage II/III non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 499-505.
  • Vis forfatter(e) (2011). Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian testicular cancer group. Journal of Clinical Oncology. 2032-2039.
  • Vis forfatter(e) (2011). MicroRNA-15b is induced with E2F-controlled genes in HPV-related cancer. British Journal of Cancer. 1719-1725.
  • Vis forfatter(e) (2011). Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group. Journal of Clinical Oncology. 719-725.
  • Vis forfatter(e) (2011). Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLOS ONE. 13 sider.
  • Vis forfatter(e) (2010). Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980-2007. Cancer Detection and Prevention. 359-367.
  • Vis forfatter(e) (2010). Prognostic Impact of VEGF and VEGF Receptor 1 (FLT1) Expression in Patients Irradiated for Stage II/III Non-Small Cell Lung Cancer (NSCLC). Strahlentherapie und Onkologie (Print). 307-314.
  • Vis forfatter(e) (2010). Paternity and Testicular Function Among Testicular Cancer Survivors Treated With Two to Four Cycles of Cisplatin-Based Chemotherapy. European Urology. 134-140.
  • Vis forfatter(e) (2010). Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study. Annals of Oncology. 1858-1863.
  • Vis forfatter(e) (2010). Late side effects and quality of life after radiotherapy for rectal cancer. International Journal of Radiation Oncology, Biology, Physics. 1005-1011.
  • Vis forfatter(e) (2010). Late side effects and quality of life after radiotherapy for rectal cancer. International Journal of Radiation Oncology, Biology, Physics. 1005-1011.
  • Vis forfatter(e) (2010). Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. Journal of Clinical Oncology. 4649-4657.
  • Vis forfatter(e) (2010). Alternative Cyclin D1 Splice Forms Differentially Regulate the DNA Damage Response. Cancer Research. 8802-8811.
  • Vis forfatter(e) (2010). A study of coping in long-term testicular cancer survivors. Psychology, Health & Medicine. 146-158.
  • Vis forfatter(e) (2010). A controlled study of risk factors for disease and current problems in long-term testicular cancer survivors. Journal of cancer survivorship. 256-265.
  • Vis forfatter(e) (2009). cDNA microarray analysis of serially sampled cervical cancer specimens from patients treated with thermochemoradiotherapy. International Journal of Radiation Oncology, Biology, Physics. 1562-1569.
  • Vis forfatter(e) (2009). Utilisation of specialist care in patients with incurable rectal cancer. A population-based study from Western Norway. Acta Oncologica. 377-384.
  • Vis forfatter(e) (2009). Topographical distribution of choroidal naevi in the ocular fundus. Eye (London. 1987). 1685-1690.
  • Vis forfatter(e) (2009). The personality trait of neuroticism is strongly associated with long-term morbidity in testicular cancer survivors. Acta Oncologica. 842-849.
  • Vis forfatter(e) (2009). SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nature Genetics. 1238-1242.
  • Vis forfatter(e) (2009). Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program. Journal of Clinical Oncology. 2122-2128.
  • Vis forfatter(e) (2009). Rectal cancer with macroscopic peritoneal involvement - clinical challenges and consequences. Colorectal Disease. 838-844.
  • Vis forfatter(e) (2009). Pulmonary Function in Long-Term Survivors of Testicular Cancer. Journal of Clinical Oncology. 2779-2786.
  • Vis forfatter(e) (2009). Outcome in intermediate or high risk prostate cancer patients receiving radiation dose and hormone therapy. Acta Oncologica. 874-881.
  • Vis forfatter(e) (2009). Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors. Journal of the National Cancer Institute. 1682-1695.
  • Vis forfatter(e) (2009). Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors. Journal of the National Cancer Institute. 1682-1695.
  • Vis forfatter(e) (2009). Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor. International Journal of Hyperthermia. 41-46.
  • Vis forfatter(e) (2009). Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicenter randomized trial by The European Society for Hyperthermic Oncology. International Journal of Hyperthermia. 323-334.
  • Vis forfatter(e) (2009). Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncologica. 368-376.
  • Vis forfatter(e) (2009). Fear of recurrence in long-term testicular cancer survivors. Psycho-Oncology. 580-588.
  • Vis forfatter(e) (2009). Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. British Journal of Cancer. 1282-1289.
  • Vis forfatter(e) (2009). Duration of symptoms, stage at diagnosis and relative survival in colon and rectal cancer. European Journal of Cancer. 2383-2390.
  • Vis forfatter(e) (2008). Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. Journal of cancer survivorship. 128-137.
  • Vis forfatter(e) (2008). Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. Journal of cancer survivorship. 128-137.
  • Vis forfatter(e) (2008). Posterior uveal melanoma. Distribution of the sites of origin and patterns of tumour extent in the ocular fundus. British Journal of Ophthalmology. 751-756.
  • Vis forfatter(e) (2008). Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation. Eye (London. 1987). 1398-1403.
  • Vis forfatter(e) (2008). Palliative surgery for rectal cancer in a national cohort. Colorectal Disease. 336-343.
  • Vis forfatter(e) (2008). Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity. International Journal of Radiation Oncology, Biology, Physics. 1478-1486.
  • Vis forfatter(e) (2008). Incidence of iris melanoma in western Norway. Acta Ophthalmologica. 116-117.
  • Vis forfatter(e) (2008). Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. Radiotherapy and Oncology. 435-442.
  • Vis forfatter(e) (2008). Global gene expression analyses reveal changes in biological processes after hyperthermia in a rat glioma model. International Journal of Hyperthermia. 425-441.
  • Vis forfatter(e) (2008). Gene expression reveals two distinct groups of anal carcinomas with clinical implications. British Journal of Cancer. 1264-1273.
  • Vis forfatter(e) (2008). Fear of recurrence in long-term testicular cancer survivors. Psycho-Oncology.
  • Vis forfatter(e) (2008). Dynamic contrast enhanced magnetic resonance imaging of bladder cancer and implications for biological image-adapted radiotherapy. Acta Oncologica. 1257-1264.
  • Vis forfatter(e) (2008). Dynamic contrast enhanced magnetic resonance imaging of bladder cancer and implications for biological image-adapted radiotherapy. Acta Oncologica. 1257-1264.
  • Vis forfatter(e) (2008). Current status of antivascular therapy and targeted treatment in the clinic. International Journal of Hyperthermia. 97-110.
  • Vis forfatter(e) (2008). Chronic cancer-related fatigue in long-term survivors of testicular cancer. Journal of Psychosomatic Research. 363-371.
  • Vis forfatter(e) (2007). Transient neurological adverse effects following low dose radiation therapy for early stage testicular seminoma. Radiotherapy and Oncology. 137-144.
  • Vis forfatter(e) (2007). Time patterns of changes in biomarkers, symptoms and histopathology during pelvic radiotherapy. Acta Oncologica. 639-650.
  • Vis forfatter(e) (2007). Strålebehandling av endetarmskreft. Tidsskrift for Den norske legeforening. 3090-3093.
  • Vis forfatter(e) (2007). Quantification of S100A12 (EN-RAGE) in blood varies with sampling method, calcium and heparin. Scandinavian Journal of Immunology. 192-201.
  • Vis forfatter(e) (2007). Is the sexual function compromised in long-term testicular cancer survivors? European Urology. 1438-1447.
  • Vis forfatter(e) (2007). Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncologica. 480-489.
  • Vis forfatter(e) (2007). Components of the metabolic syndrome in long-term survivors of testicular cancer. Annals of Oncology. 241-248.
  • Vis forfatter(e) (2007). Clinical characteristics and outcomes in patients with advanced rectal cancer: A national prospective cohort study. Diseases of the Colon & Rectum. 285-291.
  • Vis forfatter(e) (2007). Adjuvant kjemoterapi ved tykktarmskreft. Tidsskrift for Den norske legeforening. 3094-3096.
  • Vis forfatter(e) (2006). Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer. Acta Oncologica. 454-462.
  • Vis forfatter(e) (2006). Components of the metabolic syndrome in long-term survivors of testicular cancer. Annals of Oncology.
  • Vis forfatter(e) (2006). A concomitant tumour boost in bladder irradiation: Patient suitability and the potential of intensity-modulated radiotherapy. Radiotherapy and Oncology. 98-105.
  • Vis forfatter(e) (2005). The assosiation between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men i general population sample. Supportive Care in Cancer. 637-646.
  • Vis forfatter(e) (2005). The association between self-reported physical activity and prevalence of depression and anxiety disorders in long-term survivors of testicular cancer and men in the general population sample. Supportive Care in Cancer. 637-646.
  • Vis forfatter(e) (2005). The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample. Supportive Care in Cancer. 637-646.
  • Vis forfatter(e) (2005). Testing the new ICRU 62 'Planning Organ at Risk Volume' concept for the rectum. Radiotherapy and Oncology. 293-302.
  • Vis forfatter(e) (2005). Study of anxiety disorder and depression in long-term survivors of testicular cancer. Journal of Clinical Oncology. 2389-2395.
  • Vis forfatter(e) (2005). Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. Journal of Clinical Oncology. 3061-3068.
  • Vis forfatter(e) (2005). SSucralfate does not ameliorate acute radiation proctitis: Randomised study and meta-analysis. Clinical Oncology. 485-491.
  • Vis forfatter(e) (2005). Paternity following treatment for testicular cancer. Journal of the National Cancer Institute. 1580-1588.
  • Vis forfatter(e) (2005). Paternity following treatment for testicular cancer. Journal of the National Cancer Institute. 1580-1588.
  • Vis forfatter(e) (2005). Paternity following treatment for testicular cancer. Journal of the National Cancer Institute. 1580-1588.
  • Vis forfatter(e) (2005). Paternity Following Treatment for Testicular Cancer. Journal of the National Cancer Institute. 1580-1588.
  • Vis forfatter(e) (2005). Blood pressure and body mass index in long-term survivors of testicular cancer. Journal of Clinical Oncology. 4980-4990.
  • Vis forfatter(e) (2005). Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncologica. 904-912.
  • Vis forfatter(e) (2005). Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncologica. 904-912.
  • Vis forfatter(e) (2004). Updated European core curriculum for radiotherapists (radiation oncologists). Recommended curriculum for the specialist training of medical practitioners in radiotherapy (radiation oncology) within Europe. Radiotherapy and Oncology. 107-113.
  • Vis forfatter(e) (2004). Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncologica. 495-498.
  • Vis forfatter(e) (2004). Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. Radiotherapy and Oncology. 291-304.
  • Vis forfatter(e) (2004). On the use of margins for geometrical uncertainties around the rectum in radiotherapy planning. Radiotherapy and Oncology. 11-19.
  • Vis forfatter(e) (2004). Multiple sclerosis in Nord-Trondelag County, Norway: a prevalence and incidence study. Acta Neurologica Scandinavica. 378-384.
  • Vis forfatter(e) (2004). Multicentre phase II study of Nordic 5-fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology. 31-38.
  • Vis forfatter(e) (2004). Karnydanning og tumorkar som mål for kreftterapi. Tidsskrift for Den norske legeforening. 1919-1922.
  • Vis forfatter(e) (2004). Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: A pilot study of eight stool markers. Scandinavian Journal of Gastroenterology. 1113-1118.
  • Vis forfatter(e) (2004). Evaluation of a new method for calculation of cumulative doses in the rectum wall using repeat CT scans. Acta Oncologica. 388-395.
  • Vis forfatter(e) (2004). Blood pressure and body mass index (BMI) in testicular cancer survivors. Annals of Oncology. 112-112.
  • Vis forfatter(e) (2004). Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiotherapy and Oncology. 43-53.
  • Vis forfatter(e) (2004). A Monte Carlo study of the impact of the choice of rectum volume definition on estimates of equivalent uniform doses and the volume parameter. Physics in Medicine and Biology. 3341-3352.
  • Vis forfatter(e) (2003). The level of physical activity in long-term survivors of testicular cancer. European Journal of Cancer. 1216-1221.
  • Vis forfatter(e) (2003). The level of physical activity in long-term surdivors of testicular cancer. European Journal of Cancer. 6 sider.
  • Vis forfatter(e) (2003). Sustained Prothrombotic profile after Hip Replacement Surgery. The Influence of Prolonged Prophylaxis with Dalteparin. Thrombosis and Haemostasis. 971-975.
  • Vis forfatter(e) (2003). Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate. Acta Oncologica. 741-748.
  • Vis forfatter(e) (2003). Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. Radiotherapy and Oncology. 291-304.
  • Vis forfatter(e) (2003). Nordic 5-Fluorouracil/Leucovorin bolus schedule combined with Oxaliplatin (Nordic FLOX)as first-line treatment of metastatic colorectal cancer. Acta Oncologica. 827-831.
  • Vis forfatter(e) (2003). Gonadal hormones in longterm survivors 10 years after treatment for unilateral testicular cancer. European Urology. 322-328.
  • Vis forfatter(e) (2003). Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. European Urology. 322-328.
  • Vis forfatter(e) (2003). Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. European Urology. 7 sider.
  • Vis forfatter(e) (2003). Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. European Urology. 322-328.
  • Vis forfatter(e) (2003). Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to Oxaliplatin combination chemotherapy: Implications for tumor marker monitoring and guidelines. Journal of Clinical Oncology. 4466-4467.
  • Vis forfatter(e) (2003). Brachytherapy for prostatic cancer: a systematic review of clinical and cost effectiveness. European Urology. 40-46.
  • Vis forfatter(e) (2003). Brachytherapy for prostate cancer: A systematic review of clinical and cost effectiveness. European Urology. 40-46.
  • Vis forfatter(e) (2002). The influence of combretastatin A-4 and vinblastine on interstitial fluid pressure in BT4An rat gliomas. Cancer Letters. 209-217.
  • Vis forfatter(e) (2002). Norwegian Oncologists' Expectations of Intensity-modulated Radiotherapy. Acta Oncologica. 562-565.
  • Vis forfatter(e) (2002). Hyperthermia exhibits anti-vascular activity in the s.c. BT4An rat glioma: lack of interaction with the angiogenesis inhibitor batimastat. International Journal of Hyperthermia. 141-152.
  • Vis forfatter(e) (2002). Cardiac and pulmonary doses and complication probabilities in standard and conformal tangential irradiation in conservative management of breast cancer. Radiotherapy and Oncology. 173-183.
  • Vis forfatter(e) (2002). Brakyterapi ved prostatakreft. Tidsskrift for Den norske legeforening. 2795-2798.
  • Vis forfatter(e) (2001). Vinblastine and hyperthermia target the neovasculature in BT(4)AN rat gliomas: therapeutic implications of the vascular phenotype. International Journal of Radiation Oncology, Biology, Physics. 535-544.
  • Vis forfatter(e) (2001). Tumor vasculature is targeted by the combination of combretastatin A-4 and hyperthermia. Radiotherapy and Oncology. 313-320.
  • Vis forfatter(e) (2001). Partially wedged beams improve radiotherapy treatment of urinary bladder cancer. Radiotherapy and Oncology. 21-30.
  • Vis forfatter(e) (2001). Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and hemolysis. Case report. Acta Oncologica. 882-883.
  • Vis forfatter(e) (2001). Dosimetric verification of a dedicated 3D treatment planning system for episcleral plaque therapy. International Journal of Radiation Oncology, Biology, Physics. 1159-1166.
  • Vis forfatter(e) (2001). Combretastatin A-4 and hyperthermia; a potent combination for the treatment of solid tumors. Radiotherapy and Oncology. 147-154.
  • Vis forfatter(e) (2001). Cardiac and pulmonary doses and complication probabilities in standard and conformal tangential irradiation in conservative management of breast cancer. Radiotherapy and Oncology. 11 sider.
  • Vis forfatter(e) (2001). Can dose-response models predict reliable normal tissue complication probabilities in radical radiotherapy of urinary bladder cancer? The impact of alternative radiation tolerance models and parameters. International Journal of Radiation Oncology, Biology, Physics. 627-637.
  • Vis forfatter(e) (2001). Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. The Lancet. 1291-1304.
  • Vis forfatter(e) (2000). The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. International Journal of Radiation Oncology, Biology, Physics. 645-652.
  • Vis forfatter(e) (2000). The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. International Journal of Radiation Oncology, Biology, Physics. 645-652.
  • Vis forfatter(e) (2000). Partially wedged fields formed by dynamic collimation. Medical Physics (Lancaster). 527-534.
  • Vis forfatter(e) (2000). Partially wedged fields formed by dynamic collimation. Medical Physics (Lancaster). 527-534.
  • Vis forfatter(e) (2000). Dose-volume analysis of different stereotactic radiotherapy mono-isosentric techniques. Acta Oncologica. 157-163.
  • Vis forfatter(e) (2000). Dose-volume analysis of different stereotactic radiotherapy mono-isocentric techniques. Acta Oncologica. 157-163.
  • Vis forfatter(e) (2000). Behandling av nyrekreft med fjernmetastaser. Tidsskrift for Den norske legeforening. 2274-2278.
  • Vis forfatter(e) (2000). Behandling av nyrekreft med fjernmetastaser. Tidsskrift for Den norske legeforening. 2274-2278.
  • Vis forfatter(e) (2000). Behandling av nyrekreft med fjernmetastaser. Tidsskrift for Den norske legeforening. 2274-2278.
  • Vis forfatter(e) (2000). Adapting the waterproof BMS-96 diode array for isodose measurements of intensity modulated beams. Medical Dosimetry. 93-97.
  • Vis forfatter(e) (2000). Adapting the waterproof BMS-96 diode array for isodose measurements of intensity modulated beams. Medical Dosimetry. 93-97.
  • Vis forfatter(e) (2000). ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC). Radiotherapy and Oncology. 111-119.
  • Vis forfatter(e) (2000). ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC). Radiotherapy and Oncology. 111-119.
  • Vis forfatter(e) (1999). Tissue prostate-specific antigen and androgen receptor immunoreactivity in prostate cancer biopsies before, during and after neo-adjuvant androgen deprivation followed by radiotherapy. European Urology. 116-122.
  • Vis forfatter(e) (1999). Tissue Prostate-Specific Antigen and Androgen Receptor Immunoreactivity in Prostate Cancer Biopsies before, during and after Neo-Adjuvant Androgen Deprivation Followed by Radiotherapy. European Urology. 116-122.
  • Vis forfatter(e) (1999). Tissue PSA and androgen receptor immunoreactivity in prostate cancer biopsies before, during and after neo-adjuvant androgen deprivation followed by radiotherapy. European Urology. 116-122.
  • Vis forfatter(e) (1999). Status of clinical hyperthermia. Acta Oncologica. 863-873.
  • Vis forfatter(e) (1999). ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by EORTC. Radiotherapy and Oncology. 149-156.
  • Vis forfatter(e) (1998). Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. Urology. 833-834.
  • Vis forfatter(e) (1998). Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. Urology. 833-834.
  • Vis forfatter(e) (1997). for the Swedish-Norwegian Testis Cancer Group (SWENOTECA). European Journal of Cancer. 1038-1044.
  • Vis forfatter(e) (1997). Risk-adapted treatment of clinical stage I nonseminoma testis cancer. European Journal of Cancer. 1038-1044.
  • Vis forfatter(e) (1997). Risk-adapted treatment of clinical stage I non-seminaoma testis cancer. European Journal of Cancer. 1038-1044.
  • Vis forfatter(e) (1997). Quality assurance in conformal radiotherapy. DYNARAD consensus report on pratice guidelines. Radiotherapy and Oncology. 217-223.
  • Vis forfatter(e) (1997). Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. British Journal of Cancer. 1744-1762.
  • Vis forfatter(e) (1997). Fibrosarcoma in children. A rare tumour with long-term survival even with advanced disease. A report of 3 cases. Acta Oncologica. 438-440.
  • Vis forfatter(e) (1997). Fibrosarcoma in children. Acta Oncologica. 438-440.
  • Vis forfatter(e) (1996). Use of the vasodilator sodium nitroprusside during local hyperthermia: Effects on tumor temperature and tumor response in a rat tumor model. International Journal of Radiation Oncology, Biology, Physics. 403-415.
  • Vis forfatter(e) (1996). Clinical assessment of conformal radiotherapy results. Acta Oncologica. 41-57.
  • Vis forfatter(e) (1996). Cisplatin-based chemotherapy in a renal transplant recipient with metastatic germ cell testicular cancer. Acta Oncologica. 759-761.
  • Vis forfatter(e) (1995). The use of non-proven therapy among patients treated in Norwegian oncological departments. A cross-sectional national multicentre study. European Journal of Cancer. 1785-1789.
  • Vis forfatter(e) (1995). Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. The Lancet. 540-543.
  • Vis forfatter(e) (1993). Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of vater - Results of a controlled, prospective, randomised multicentre study. European Journal of Cancer. 698-703.
  • Vis forfatter(e) (1978). A syndrome of factor VVI deficiency and abnormal platelet release reaction. Scandinavian Journal of Haematology. 206-214.
Vitenskapelig foredrag
  • Vis forfatter(e) (2014). Management of clinical stage I seminomatous testicular cancer: A report from SWENOTECA.
  • Vis forfatter(e) (2006). The present conditions and the future prospects of clinical test of hyperthermia in Europe.
  • Vis forfatter(e) (2006). Posterior uveal melanoma. Distribution of initiation sites and patterns of tumour extent in the ocular fundus.
  • Vis forfatter(e) (2005). Gonadal hormones, sperm counts and post-treatment paternity in long-term survivors of unilateral testicular cancer.
  • Vis forfatter(e) (2005). Får pasienter med lokalisert prostatakreft adekvat tilbud om radikal strålebehandling?
  • Vis forfatter(e) (2005). A randomised phase III multicenter trial comparing irinotecan in combination with 5FU and folinic acid (FU/FA) given according to the Nordic bolus schedule to irinotecan in combination with 5FU/FA given according to the bolus/infused de Gramont schedule, in patients with metastatic colorectal cancer.
  • Vis forfatter(e) (2005). A concomitant tumour boost in bladder irradiation: Patient suitability and the potensial of intensity-modulated radiotherapy.
  • Vis forfatter(e) (2004). Post-treatment paternity in testicular cancer survivors.
  • Vis forfatter(e) (2004). Post-treatment paternity in testicular cancer survivors.
  • Vis forfatter(e) (2004). Dose response in a series of 495 patients with early prostate cancer.
  • Vis forfatter(e) (2004). Blood pressure and body mass index (BMI) in testicular cancer survivors.
  • Vis forfatter(e) (2004). Blood pressure and Body mass index in testicular cancer survivors.
  • Vis forfatter(e) (2004). A test of the ICRU 62 "Planning organ at Risk Volume" concept for the rectum.
  • Vis forfatter(e) (2004). A Monte Carlo study of the impact of the choice of rectum volume definition on estimates of the equivalent uniform doses and the volume parameter.
  • Vis forfatter(e) (2003). Regional hyperthermia added to chemoradiotherapy in advanced cervical cancer: Multicenter international feasibility.
  • Vis forfatter(e) (2003). Only colon cancer patients with Dukes stage C benefit from adjuvant chemotherapy with 5-fluorouracil and levamisole among 425 patients with operable colorectal cancer in a Norwegian randomised study.
  • Vis forfatter(e) (2003). Adjuvant chemotherapy in colorectal cancer: Joint analyses of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
  • Vis forfatter(e) (2001). Verification of a 3-D treatment planning system for episcleral brachytherapy.
  • Vis forfatter(e) (2001). Cardiac and pulmonary doses and complication probabilities in standard and conformal tangential irradiation in conservative management of breast cancer.
Sammendrag/abstract
  • Vis forfatter(e) (2014). Scandinavian studies of gene variants and risk of testicular germ cell tumor. 8th CIS Abstract book.
  • Vis forfatter(e) (2014). Particle therapy in Norway - report from the national project group. Radiotherapy and Oncology. 314-314.
  • Vis forfatter(e) (2013). Investigation of six testicular germ cell tumor susceptibility genes suggests a parent-of-origin effect in the tumor suppressor gene SPRY4. Norsk Epidemiologi, Supplement. 44-44.
  • Vis forfatter(e) (2012). Bilateral testicular cancer within two prospective, population-based SWENOTECA protocols in clinical stage I nonseminoma. Journal of Clinical Oncology. 1 sider.
  • Vis forfatter(e) (2009). Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA. Journal of Clinical Oncology. 2 sider.
  • Vis forfatter(e) (2008). Topographical distribution of posterior uveal melanoma, choroidal nevi, and congenital hypertrophy of the retinal pigment epithelium. Acta Ophthalmologica. 8-8.
  • Vis forfatter(e) (2008). Rectal cancer with macroscopic peritoneal involvement - clinical challenges and consequences. Colorectal Disease. 23 sider.
  • Vis forfatter(e) (2008). Pulmonary function in long-term testicular cancer survivors. Annals of Oncology. viii205.
  • Vis forfatter(e) (2007). Is neuroticism associated with long-term morbidity in testicular cancer survivors? Psycho-Oncology.
  • Vis forfatter(e) (2007). Fear of recurrence in long-term testicular cancer survivors. Psycho-Oncology.
  • Vis forfatter(e) (2006). Self-reported paresthesias, Raynaud's phenomena, tinnitus, and hearing impairment in a large cohort of long-term testicular cancer (TG) survivors. Journal of Clinical Oncology. 228S-228S.
  • Vis forfatter(e) (2006). Self-reported paresthesia, Raynaud,s phenomena, tinnitus, and hearing impairment in long-term testicular cancer (TC) survivors. Journal of Clinical Oncology. 228s.
  • Vis forfatter(e) (2006). Cardiovascular (CV)morbidity and predicted mortality in long-term testicular cancer (TC) survivors. Annals of Oncology. 443PD.
  • Vis forfatter(e) (2005). Self-reported paresthesia, Raynaud’s phenomena, tinnitus, and hearing impairment in long-term testicular cancer (TC) survivors. European Journal of Cancer.
  • Vis forfatter(e) (2005). Metabolic syndrome in long-term testicular cancer survivors. Proceedings of the Annual Meeting of the American Society for Clinical Oncology.
  • Vis forfatter(e) (2005). Metabolic syndrome in long-term testicular cancer survivors. Journal of Clinical Oncology.
  • Vis forfatter(e) (2005). Gonadal hormones, sperm counts and post-treatment paternity in long-term survivors of unilateral testicular cancer. European Journal of Cancer. 228s.
  • Vis forfatter(e) (2004). Working ability and educational level among long-term survivors of teasticular cancer (TCSS) compared to a general population (GenPop). Proceedings of the Annual Meeting of the American Society for Clinical Oncology. 1 sider.
  • Vis forfatter(e) (2004). Testing the new ICRU 62 'planning organ at risk volume' concept for the rectum. Radiotherapy and Oncology.
  • Vis forfatter(e) (2004). Post-treatment paternity in testicular cancer survivors. Proceedings of the Annual Meeting of the American Society for Clinical Oncology. 1 sider.
  • Vis forfatter(e) (2004). Post-treatment paternity in testicular cancer survivors. Journal of Clinical Oncology. 388S-388S.
  • Vis forfatter(e) (2004). Blood pressure and body mass index (BMI) in testicular cancer survivors. Annals of Oncology. 112-112.
  • Vis forfatter(e) (2003). Treatment precision and treatment effect in conformal radiotherapy of urinary bladder cancer - preliminary results. Radiotherapy and Oncology. S94-S94.
  • Vis forfatter(e) (2003). Risk-adapted brief adjuvant chemotherapy in clinical stage I (CSI) nonseminomatous germ cell testicular cancer (NSGCT). Proceedings of the Annual Meeting of the American Society for Clinical Oncology. 1 sider.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2009). Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. European Journal of Pharmacology. 6-22.
  • Vis forfatter(e) (2008). Analkreft. Tidsskrift for Den norske legeforening. 198-200.
  • Vis forfatter(e) (2004). Conformal radiotherapy of urinary bladder cancer. Radiotherapy and Oncology. 387-398.

Se fullstendig oversikt over publikasjoner i CRIStin.